Endocrine Abstracts

Objectives: Hürthle cell (oncocytic) lesions can be metaplastic or neoplastic events. The neoplastic entities -formerly, oncocytic variant of follicular tumours; Hürthle cell neoplasm (HCN) - include HC adenomas and HC carcinomas and have been recognized as a separate class of tumours by the WHO. The remaining of the thyroid tumours demonstrating “mitochondrion-rich cells” and oncocytic morphology are referred under the umbrella term of “oncocytic vari...

Objectives: Somatic copy number alterations (SCNAs) have been the most common genetic alterations identified in cancer, that frequently related with extensive genomic instability and to an aggressive behavior. Hürthle cell carcinoma is known to be aggressive, having the highest incidence of recurrences, distant metastasis and RAI therapy resistance among all differentiated follicular cell derived thyroid carcinomas. Due to these differences and recent molecular discoverie...

Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers.Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTC).<p class="abstext"...